Venglustat (GZ/SAR402671)

Small molecule

Filedunder review

Evidence outlook · regulatory review

Gaucher Disease: application under FDA review, decision date 2026-11-25

FDA accepts venglustat NDA for GD3 (2026-05-28). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Development in Parkinson's Disease stopped (2020-12-18) after a negative readout. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Gaucher Disease
NCT07927140 · Sanofi
2026-12-11 – 2031-03-03 · Gaucher's Disease Type III
What this study did
NCT05222906 · Sanofi
2022-04-18 – 2026-10-30 · Gaucher's Disease Type III
What this study did
Phase 2 (2)
Gaucher Disease
NCT02843035 · Genzyme, a Sanofi Company
2017-01-04 – 2026-10-30 · Gaucher Disease Type 1, Gaucher Disease Type 3
What this study did
Other / comorbidity
NCT02906020 · Genzyme, a Sanofi Company
2016-12-15 – 2021-05-27 · Parkinson's Disease
What this study did
Phase 1 (1)
Other / comorbidity
NCT06421714 · Genzyme, a Sanofi Company
2018-08-16 – 2018-10-14 · Healthy Volunteers
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Venglustat (GZ/SAR402671) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
January 2030 (1)
Phase 3Gaucher DiseaseNot yet recruiting
Est. primary completion 2030-01-14 · NCT07927140 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

25 November 2026FDA action datePDUFA target action date set for venglustat
US, FDA · Source ↗

Recent

28 May 2026Priority reviewFDA grants priority review to venglustat NDA for GD3
US, FDA · Source ↗
28 May 2026Filing acceptedFDA accepts venglustat NDA for GD3
US, FDA · Source ↗